<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0124-7107</journal-id>
<journal-title><![CDATA[Universidad y Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Univ. Salud]]></abbrev-journal-title>
<issn>0124-7107</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Nariño]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0124-71072022000200184</article-id>
<article-id pub-id-type="doi">10.22267/rus.222402.271</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Aplicaciones terapéuticas del eculizumab]]></article-title>
<article-title xml:lang="en"><![CDATA[Therapeutic applications of eculizumab]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Campos-González]]></surname>
<given-names><![CDATA[Natalia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ruiz-Jiménez]]></surname>
<given-names><![CDATA[Susana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Jiménez]]></surname>
<given-names><![CDATA[Johanna]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chacón-Jiménez]]></surname>
<given-names><![CDATA[Luz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Costa Rica Facultad de Farmacia ]]></institution>
<addr-line><![CDATA[San José de Costa Rica ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Costa Rica Instituto de Investigaciones en Salud (INISA) ]]></institution>
<addr-line><![CDATA[San José de Costa Rica ]]></addr-line>
<country>Costa Rica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2022</year>
</pub-date>
<volume>24</volume>
<numero>2</numero>
<fpage>184</fpage>
<lpage>196</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0124-71072022000200184&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0124-71072022000200184&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0124-71072022000200184&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: El eculizumab es un anticuerpo monoclonal de tipo IgG diseñado para el tratamiento de la hemoglobinuria paroxística nocturna (HPN), en el que su diana farmacológica forma parte del sistema del complemento. Su mecanismo de acción ha permitido implementarlo en el tratamiento de enfermedades huérfanas, como el síndrome urémico hemolítico atípico (SUHa), trastorno del espectro de la neuromielitis óptica (TENMO) y miastenia gravis, cuya incidencia, es baja. Asimismo, es viable en el tratamiento de Guillain Barré y el síndrome antifosfolípido catastrófico (CAPS).  Objetivo: Evidenciar aplicaciones terapéuticas del eculizumab y beneficios más significativos en algunos padecimientos.  Materiales y métodos: Se realizó búsqueda bibliográfica en el periodo 2010-2021, en bases de datos: Google Scholar, Science Direct, PubMed y Scielo, utilizando como palabra clave &#8220;eculizumab&#8221;. Posteriormente, se afinó la búsqueda utilizando palabras claves asociadas a enfermedades tratadas con este medicamento.  Resultados: Se identificó el mecanismo de acción del fármaco y su efecto sobre la patogénesis de hemoglobinuria paroxística nocturna, síndrome urémico atípico, miastenia gravis generalizada refractaria, trastorno del espectro de la neuromielitis óptica, síndromes antifosfolípidos catastrófico y Guillain-Barré.  Conclusiones: El eculizumab tiene una alta seguridad y capacidad para tratar y disminuir síntomas de diversas enfermedades que involucran el sistema del complemento.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Eculizumab is an IgG type monoclonal antibody designed to treat paroxysmal nocturnal hemoglobinuria (PNH) and its pharmacological target is a member of the complement system. Its mechanism of action has permitted its use in the treatment of orphan diseases such as atypical hemolytic uremic syndrome (aHUS), neuromyelitis optic spectrum disorder (NMOSD), and myasthenia gravis, all of which have a low incidence. Likewise, eculizumab is a viable treatment for Guillain Barré and catastrophic antiphospholipid syndrome (CAS).  Objective: To describe the therapeutic applications of eculizumab and its most significant benefits in some illnesses.  Materials and methods: A bibliographic search was carried out during the 2010-2021 period in Google Scholar, Science Direct, PubMed and Scielo databases using the keyword eculizumab. Then, the search was refined by using keywords associated with diseases treated with this medication.  Results: The mechanism of action of the antibody and its effect on the pathogenesis of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, refractory generalized myasthenia gravis, neuromyelitis optic spectrum disorder, catastrophic antiphospholipid syndrome, and Guillain Barré were identified.  Conclusions: Eculizumab has high safety and capacity in treating and diminishing symptoms of diverse illnesses, which involve the complement system.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Eculizumab]]></kwd>
<kwd lng="es"><![CDATA[activación de complemento]]></kwd>
<kwd lng="es"><![CDATA[inmunoglobulinas, enfermedades raras]]></kwd>
<kwd lng="en"><![CDATA[Eculizumab]]></kwd>
<kwd lng="en"><![CDATA[complement activation]]></kwd>
<kwd lng="en"><![CDATA[immunoglobulins]]></kwd>
<kwd lng="en"><![CDATA[rare diseases]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loirat]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Frémeaux-Bacchi]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atypical hemolytic uremic syndrome]]></article-title>
<source><![CDATA[Orphanet J Rare Dis]]></source>
<year>2011</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>60</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Francesc]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eculizumab: farmacología clínica]]></article-title>
<source><![CDATA[Elsevier]]></source>
<year>2012</year>
<volume>13</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>21-4</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dhillon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eculizumab: A Review in Generalized Myasthenia Gravis]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2018</year>
<volume>78</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>367-76</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brodsky]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eculizumab]]></article-title>
<source><![CDATA[Hematología]]></source>
<year>2013</year>
<volume>17</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>276-84</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kindt]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Goldsby]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Osborne]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
</person-group>
<source><![CDATA[Inmunología de Kuby]]></source>
<year>2014</year>
<edition>6</edition>
<publisher-loc><![CDATA[Mexico ]]></publisher-loc>
<publisher-name><![CDATA[McGraw-Hill]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<collab>Lexicomp</collab>
<source><![CDATA[Eculizumab: Drug information]]></source>
<year>2020</year>
<publisher-name><![CDATA[UpToDate]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cicora]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Roberti]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mos]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Paz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilización de Eculizumab en un receptor de transplante renal con altos títulos de anticuerpos preformados anti-HLA donante específico]]></article-title>
<source><![CDATA[Rev Nefrol Dialisis Transpl]]></source>
<year>2013</year>
<volume>33</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>92-6</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nieto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zuluaga]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bello]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trasplante renal exitoso con protocolo de eculizumab, timoglobulina, tacrolimus, micofenolato y esteroides en paciente con síndrome hemolítico urémico atípico sin mutación identificada]]></article-title>
<source><![CDATA[NefroPlus]]></source>
<year>2018</year>
<volume>10</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>63-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Morado]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gaya]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ojeda]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento de la hemoglobinuria paroxística nocturna con eculizumab: experiencia en España]]></article-title>
<source><![CDATA[Med Clin]]></source>
<year>2011</year>
<volume>137</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>8-13</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>Comisión Revisora: Sala Especializada de Moléculas nuevas, nuevas Indicaciones y Medicamentos Biológicos</collab>
<source><![CDATA[]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<collab>Consejo de Salubridad General</collab>
<collab>Comisión Interinstitucional del Cuadro Básico y Catálogo de Insumos del Sector Salud</collab>
<collab>Comité Técnico Específico de Medicamentos</collab>
<source><![CDATA[Evolución del Proceso del Cuadro Básico y Catálogo de Medicamentos: Período 24-04-2019 al 11-06-19]]></source>
<year>2020</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Gobierno de México]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abbas]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Lichtman]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Pillai]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effector Mechanisms of Humoral Immunity: Elimination of Extracellular Microbes and Toxins]]></article-title>
<source><![CDATA[Basic Immunology: Functions and Disorders of the Immune System]]></source>
<year>2020</year>
<edition>6</edition>
<publisher-loc><![CDATA[Philadelphia (USA) ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patriquin]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kuo]]></surname>
<given-names><![CDATA[KHM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics]]></article-title>
<source><![CDATA[Transfus Med Rev]]></source>
<year>2019</year>
<volume>33</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>256-65</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Teirilä]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Heikkinen-Eloranta]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kotimaa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Meri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lokki]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Regulation of the complement system and immunological tolerance in pregnancy]]></article-title>
<source><![CDATA[Semin Immunol]]></source>
<year>2019</year>
<volume>45</volume>
<page-range>101337</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ricklin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Barratt-Due]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mollnes]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Complement in clinical medicine: Clinical trials, case reports and therapy monitoring]]></article-title>
<source><![CDATA[Mol Immunol]]></source>
<year>2017</year>
<volume>89</volume>
<page-range>10-21</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Atkinson]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Du Clos]]></surname>
<given-names><![CDATA[TW]]></given-names>
</name>
<name>
<surname><![CDATA[Mold]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kulkarni]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hourcade]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<source><![CDATA[21 - The Human Complement System: Basic Concepts and Clinical Relevance]]></source>
<year>2019</year>
<edition>5</edition>
<publisher-loc><![CDATA[London (UK) ]]></publisher-loc>
<publisher-name><![CDATA[Clinical Immunology]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cançado]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Araújo]]></surname>
<given-names><![CDATA[A da S]]></given-names>
</name>
<name>
<surname><![CDATA[Sandes]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Arrais]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lobo]]></surname>
<given-names><![CDATA[CL de C]]></given-names>
</name>
<name>
<surname><![CDATA[Figueiredo]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria]]></article-title>
<source><![CDATA[Hematol Transfus Cell Ther]]></source>
<year>2021</year>
<volume>43</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>341-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wijnsma]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[ter Heine]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Moes]]></surname>
<given-names><![CDATA[DJAR]]></given-names>
</name>
<name>
<surname><![CDATA[Langemeijer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Schols]]></surname>
<given-names><![CDATA[SEM]]></given-names>
</name>
<name>
<surname><![CDATA[Volokhina]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab]]></article-title>
<source><![CDATA[Clin Pharmacokinet]]></source>
<year>2019</year>
<volume>58</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>859-74</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosa]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<source><![CDATA[Monitorización farmacocinética de anticuerpos monoclonales]]></source>
<year>2016</year>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Sevilla]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Araya]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<source><![CDATA[Efecto de la Alteridad de los Aanticuerpos Equinos Sobre la Farmacocinética de los Antivenenos Ofídicos]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Costa Rica ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Costa Rica]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ryman]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Meibohm]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetics of Monoclonal Antibodies]]></article-title>
<source><![CDATA[CPT Pharmacomet Syst Pharmacol]]></source>
<year>2017</year>
<volume>6</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>576-88</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="book">
<collab>Ministerio de Sanidad</collab>
<source><![CDATA[FICHA TECNICA SOLIRIS(r) 300 mg CONCENTRADO PARA SOLUCION PARA PERFUSION]]></source>
<year>2012</year>
<publisher-name><![CDATA[Agencia Española de Medicamentos y Productos Sanitarios]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Risitano]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Marotta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria]]></article-title>
<source><![CDATA[Am J Hematol]]></source>
<year>2018</year>
<volume>93</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>564-77</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria]]></article-title>
<source><![CDATA[Hematology Am Soc Hematol Educ Program]]></source>
<year>2016</year>
<volume>2016</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>208-16</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McKeage]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2011</year>
<volume>71</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>2327-45</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kirkpatrick]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eculizumab]]></article-title>
<source><![CDATA[Nat Rev Drug Discov]]></source>
<year>2007</year>
<volume>6</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>515-6</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kelly]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Brooksbank]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Richards]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cullen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria sustained efficacy and improved survival]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2011</year>
<volume>117</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>6786-92</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brodsky]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Paroxysmal nocturnal hemoglobinuria]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2014</year>
<volume>124</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>2804-11</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Ani]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Chin-Yee]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Lazo-Langner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations]]></article-title>
<source><![CDATA[Ther Clin Risk Manag [Internet]]]></source>
<year>2016</year>
<volume>12</volume>
<page-range>1161-70</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García-Rojas]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Mora-Hernández]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hemoglobinuria paroxística nocturna]]></article-title>
<source><![CDATA[Revista Médica de Costa Rica y Centroamérica]]></source>
<year>2016</year>
<volume>73</volume>
<numero>620</numero>
<issue>620</issue>
<page-range>659-64</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sridharan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Go]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Willrich]]></surname>
<given-names><![CDATA[MAV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management]]></article-title>
<source><![CDATA[J Immunol Methods]]></source>
<year>2018</year>
<volume>461</volume>
<page-range>15-22</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Legendre]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Licht]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Muus]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Greenbaum]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Babu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bedrosian]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2013</year>
<volume>368</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2169-81</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gruppo]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Rother]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eculizumab for congenital atypical hemolytic-uremic syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2009</year>
<volume>360</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>544-6</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campistol]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Arias]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ariceta]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Blasco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Grinyó]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso]]></article-title>
<source><![CDATA[Nefrología]]></source>
<year>2013</year>
<volume>33</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>27-45</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rondeau]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cataland]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Dakkak]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Webb]]></surname>
<given-names><![CDATA[NJA]]></given-names>
</name>
<name>
<surname><![CDATA[Landau]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry]]></article-title>
<source><![CDATA[Kidney Int Rep]]></source>
<year>2019</year>
<volume>4</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1568-76</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wijnsma]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Duineveld]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Volokhina]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
<name>
<surname><![CDATA[van den Heuvel]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
<name>
<surname><![CDATA[van de Kar]]></surname>
<given-names><![CDATA[NCAJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wetzels]]></surname>
<given-names><![CDATA[JFM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2018</year>
<volume>33</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>635-45</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Covarrubias-San Martín]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Utilización de eculizumab (Soliris®) en pacientes adultos y pediátricos]]></source>
<year>2018</year>
<publisher-name><![CDATA[Universidad Complutense]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muppidi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Utsugisawa]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Benatar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Murai]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Barohn]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Illa]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term safety and efficacy of eculizumab in generalized myasthenia gravis]]></article-title>
<source><![CDATA[Muscle Nerve]]></source>
<year>2019</year>
<volume>60</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>14-24</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frampton]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2020</year>
<volume>80</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>719-27</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Israeli]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Agmon-Levin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Blank]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shoenfeld]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infections as a Cause of Guillain-Barré Syndrome]]></article-title>
<source><![CDATA[Infection and Autoimmunity]]></source>
<year>2015</year>
<edition>2</edition>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Winer]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guillain Barré syndrome]]></article-title>
<source><![CDATA[Mol Pathol]]></source>
<year>2001</year>
<volume>54</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>381-5</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de la O-Peña]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Robles-Figueroa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chávez-Peña]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Bedolla-Barajas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características del síndrome de Guillain-Barré en adultos: resultados de un hospital universitario]]></article-title>
<source><![CDATA[Rev Med Inst Mex Seguro Soc]]></source>
<year>2015</year>
<volume>53</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>678-85</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berciano]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Axonal pathology in early stages of Guillain-Barré syndrome]]></article-title>
<source><![CDATA[Neurología]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frey]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[KYC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Number of Sialic Acid Residues in Ganglioside Headgroup Affects Interactions with Neighboring Lipids]]></article-title>
<source><![CDATA[Biophys J]]></source>
<year>2013</year>
<volume>105</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1421-31</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Misawa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kuwabara]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sato]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yamaguchi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Nagashima]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Katayama]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2018</year>
<volume>17</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>519-29</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garcia-Carrasco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mendoza-Pinto]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Macias-Diaz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Vazquez de Lara]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Etchegaray-Morales]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Galvez-Romero]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of infectious diseases in the catastrophic antiphospholipid syndrome]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2015</year>
<volume>14</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1066-71</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guerra]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Zuniga]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Arenas]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Catastrophic antiphospholipid syndrome]]></article-title>
<source><![CDATA[Acta Colomb Cuid Intensivo]]></source>
<year>2019</year>
<volume>19</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>154-9</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sierra Merlano]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha Reyes]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno Grau]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome antifosfolípido catastrófico (síndrome de asherson): presentación de un caso probable]]></article-title>
<source><![CDATA[Rev Cienc Bioméd]]></source>
<year>2020</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>112-6</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kazzaz]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[McCune]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Knight]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of catastrophic antiphospholipid syndrome]]></article-title>
<source><![CDATA[Curr Opin Rheumatol]]></source>
<year>2016</year>
<volume>28</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>218-27</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ignasi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ricard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome Antifosfolliídico Catastrófico]]></article-title>
<source><![CDATA[Rev Fac Cienc Méd Univ Cuenca]]></source>
<year>2016</year>
<volume>34</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>76-87</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tinti]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Carnevale]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Inglese]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Molinaro]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bernal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Migliore]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature]]></article-title>
<source><![CDATA[Clin Exp Med]]></source>
<year>2019</year>
<volume>19</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>281-8</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yelnik]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Miranda]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mékinian]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lazaro]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Quéméneur]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Provot]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patients with refractory catastrophic antiphospholipid syndrome respond inconsistently to eculizumab]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2020</year>
<volume>136</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2473-7</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Qi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Miao]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Depei]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2021</year>
<volume>11</volume>
</nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marks]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Mamode]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Montgomery]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Stegall]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Ratner]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Cornell]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial]]></article-title>
<source><![CDATA[Am J Transplant]]></source>
<year>2019</year>
<volume>19</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2876-88</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saborío]]></surname>
<given-names><![CDATA[IE]]></given-names>
</name>
<name>
<surname><![CDATA[Durán]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Villalobos]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Síndrome urémico hemolítico en pediatría]]></article-title>
<source><![CDATA[Rev Méd Sinerg]]></source>
<year>2019</year>
<volume>4</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>55-66</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glassman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[A $400,000 Drug and Why It Matters for Global Health]]></source>
<year>2012</year>
<publisher-name><![CDATA[Center For Global Development]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
